| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Following oral administration of amygdalin to mice, peak cyanide concentrations were reached at approximately 1.5–2 hours, consistent with the concentration range following potassium cyanide administration. The ability of different gastrointestinal regions and tumor tissues to release cyanide from amygdalin was assessed. Low activity was observed in the stomach and upper small intestine, while significant amounts of cyanide were released from the lower small intestine and feces. There was considerable variability among mice. Metabolism/Metabolites Amygdalin is a chemical compound composed of glucose, benzaldehyde, and cyanide, the latter of which can be released by β-glucosidase or emulsifying enzymes. Although these enzymes are absent in mammalian tissues, the human gut microbiota appears to possess these or similar enzymes, which can promote cyanide release, leading to poisoning in humans. Therefore, oral administration of amygdalin may be up to 40 times more toxic than intravenous administration. …Plant glycosides are characterized by the production of cyanide, as well as sugars and aromatic aldehydes, upon enzymatic or acidic hydrolysis. A common example is amygdalin (gentiobiose + benzaldehyde + HCN), which is found in bitter almonds… An enzyme complex, an emulsifying enzyme, exists alongside the glycoside in plant tissues and catalyzes the hydrolysis of the glycoside, first to mandelinonitrile or p-hydroxymandelinonitrile, then to benzaldehyde or p-hydroxybenzaldehyde and HCN. The aldehydes are oxidized to the corresponding aromatic acids and excreted as peptide conjugates. …Many species of the genus Prunus contain… amygdalin, which can be hydrolyzed by emulsifying enzymes… This process does not occur in intact plants; HCN is only released when plant tissues are damaged or begin to decay. In the rumen of monogastric animals, the breakdown of glycosides generally occurs more readily or rapidly than in the digestive tract. Furthermore, small molecules can be absorbed in the rumen and rapidly enter the bloodstream. The breakdown of cyanogenic glycosides (such as amygdalin), for example, amygdalin from plants in the Rosaceae family. For more complete data on the metabolism/metabolites of amygdalin (9 in total), please visit the HSDB record page. Biological Half-Life Plasma and urine concentrations of amygdalin, as well as whole blood concentrations of CN- and SCN-, were determined after intravenous (4.5 g/m²) and oral (500 mg tablets) administration of amygdalin to cancer patients. Following intravenous administration, a parent drug concentration as high as 1401 μg/ml was observed, while plasma CN- and serum SCN- concentrations did not increase. The plasma elimination of amygdalin best conformed to a two-compartment open model, with a mean distribution phase half-life of 6.2 min, a mean elimination phase half-life of 120.3 min, and a mean clearance rate of 99.3 ml/min. Following oral administration of amygdalin, plasma concentrations decreased significantly, with peak values below 525 ng/ml. Whole blood CN- concentrations increased to as high as 2.1 μg/ml. SCN-CONCN did not increase within a few days, remaining stable at a value as high as 38 μg/mL serum. |
|---|---|
| References | |
| Additional Infomation |
New amygdalins have been reported in peach (Prunus persica), passion fruit (Passiflora edulis), and other organisms with relevant data. Amygdalin is a cyanogenic glycoside isolated from the seeds of almonds and other plants in the Rosaceae family. It can be converted to benzaldehyde, D-glucose, and hydrocyanic acid by plant emulsifying enzymes (a complex of glucosidase and nitrile hydrolase) or hydrochloric acid. (NCI04) A cyanogenic glycoside found in the seeds of Rosaceae plants.
|
| Molecular Formula |
C20H27NO11
|
|---|---|
| Molecular Weight |
457.4285
|
| Exact Mass |
457.158
|
| CAS # |
29883-16-7
|
| PubChem CID |
441462
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
223-226 °C
|
| LogP |
-2.7
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
32
|
| Complexity |
638
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
O1[C@]([H])([C@@]([H])([C@]([H])([C@@]([H])([C@@]1([H])C([H])([H])O[C@@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O1)O[H])O[H])O[H])O[H])O[H])O[H])O[C@]([H])(C#N)C1C([H])=C([H])C([H])=C([H])C=1[H]
|
| InChi Key |
XUCIJNAGGSZNQT-UUGBRMIUSA-N
|
| InChi Code |
InChI=1S/C20H27NO11/c21-6-10(9-4-2-1-3-5-9)30-20-18(28)16(26)14(24)12(32-20)8-29-19-17(27)15(25)13(23)11(7-22)31-19/h1-5,10-20,22-28H,7-8H2/t10-,11-,12-,13-,14-,15+,16+,17-,18-,19-,20-/m1/s1
|
| Chemical Name |
(S)-2-phenyl-2-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)acetonitrile
|
| Synonyms |
Neoamygdalin (S)-AmylgdalinL-Amylgdalin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~218.61 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.47 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.47 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.47 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1861 mL | 10.9306 mL | 21.8613 mL | |
| 5 mM | 0.4372 mL | 2.1861 mL | 4.3723 mL | |
| 10 mM | 0.2186 mL | 1.0931 mL | 2.1861 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05560152 | UNKNOWN STATUS | Drug: Yiqihuayu Decotion | Ischemic Stroke, Acute | Ying Gao | 2022-09-25 | Phase 2 Phase 3 |
| NCT06570668 | COMPLETED | Drug: CDD-2101 | Constipation - Functional | Centre for Chinese Herbal Medicine Drug Development Limited | 2024-05-29 | Phase 1 |